Needham Reiterates Hold on Neurocrine Biosciences
NBIXOctober 31, 2024
Read more →Neurocrine Biosciences Phase 3 KINECT-4 Post Hoc Analysis Demonstrates Clinically Meaningful And Sustained Improvement In Tardive Dyskinesia With Long-Term Use Of INGREZZA Capsules
NBIXMay 21, 2024
Read more →Neurocrine Biosciences New IBD Leaderboard Position
NBIXSeptember 8, 2022
Read more →Neurocrine Biosciences: Q1 Earnings Insights
NBIXNeurocrine Biosciences (NASDAQ:NBIX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
May 4, 2022
Read more →Neurocrine Biosciences Q1 EPS $0.30 Misses $0.34 Estimate, Sales $310.60M Beat $303.40M Estimate; Co. Reiterates FY22 Guidance
NBIXMay 4, 2022
Read more →